Zevra Therapeutics, Inc. (ZVRA) — Stock Score Summary

Zevra Therapeutics, Inc. (ZVRA) has a MoatMap StockRank of 98/100 based on Quality (85/100), Value (44/100), and Momentum (69/100) factor scores. The current signal is STRONG BUY. Zevra is a micro-cap rare disease therapeutics developer. While its recent FDA approval for Miplyffa is a positive milestone, it remains a highly speculative, pre-profit biotech company that does not meet our strict quality compounder criteria.

Zevra Therapeutics, Inc. is a rare disease therapeutics company dedicated to developing and commercializing novel treatments for patients with unmet medical needs, particularly focusing on neurological and endocrine disorders. The company strategically targets highly specialized, underserved patient populations, leveraging orphan drug designations to create a competitive advantage. Zevra is focused on advancing late-stage clinical candidates and commercializing treatments that address significant gaps in care for rare diseases.

Key Financial Metrics

Price$13.66
Market Cap$674M
P/E (TTM)5.56
P/E (Forward)5.83
Price/Book3.21
Return on Equity100.7%
Return on Invested Capital38.6%
Debt/Equity0.56
Gross Margin86.1%
Operating Margin24.4%
Revenue Growth77.5%
Free Cash Flow$26M

Zevra Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Zevra Therapeutics, Inc.’s (ZVRA) StockRank?
MoatMap’s StockRank for Zevra Therapeutics, Inc. (ZVRA) is 98/100, with a Strong Buy signal. It is a composite of Quality (85), Value (44), and Momentum (69) factor ranks across MoatMap’s 19,000+ stock universe.
Does Zevra Therapeutics, Inc. have an economic moat?
Zevra Therapeutics, Inc. (ZVRA) has a Quality factor score of 85/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Zevra Therapeutics, Inc. a buy, hold, or sell?
MoatMap’s current signal for Zevra Therapeutics, Inc. (ZVRA) is Strong Buy, based on a StockRank of 98/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Zevra Therapeutics, Inc. in?
Zevra Therapeutics, Inc. (ZVRA) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksZVRA deep dive reportAI ChampionsHow we score stocksSense-check another stock